 BOSTON--BUSINESS WIRE--Astria Therapeutics, Inc. NASDAQ:ATXS, a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema HAE, will report third quarter 2021 financial results before the Nasdaq Global Market open on Wednesday, November 10, 2021. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results. Conference Call Dial 